Dominant DNM2 mutations cause a centronuclear myopathy that is clinically characterized by progressive distal and proximal weakness beginning during infancy or even young adulthood, as well as ptosis, ophthalmoparesis, facial weakness, dysphagia and respiratory insufficiency (Bitoun et al., 2005; Hayes et al., 2022; Spiro et al., 1966). Here, DNM2 is linked to autosomal dominant centronuclear myopathy.